Back to Journals » Therapeutics and Clinical Risk Management » Volume 19 » Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
Please verify you are not a robot.